NAMSA Acquires Labcorp's Early Development Business to Enhance MedTech Services and Innovations
- NAMSA acquires Labcorp's Early Development medical device testing business, enhancing its service offerings and capabilities.
- This acquisition strengthens NAMSA's role as a comprehensive partner for MedTech manufacturers throughout the product lifecycle.
- NAMSA plans to conduct future projects for Labcorp's clients across its facilities, expanding its operational footprint.
NAMSA Expands Its Reach Through Strategic Acquisition of Labcorp's Early Development Business
NAMSA, a leading figure in medical device testing and clinical research, announces its acquisition of Labcorp's Early Development medical device testing business, a significant development that enhances its service offerings. This strategic move enables NAMSA to incorporate Labcorp’s U.S. services, which encompass a broad array of capabilities, including biocompatibility testing, microbiological testing, analytical testing, and preclinical research. By integrating these services, NAMSA strengthens its role as a comprehensive innovation partner for MedTech manufacturers, expanding its ability to support clients throughout the entire product lifecycle.
The acquisition underscores NAMSA's commitment to innovation within the MedTech sector, as highlighted by CEO Brian Smith. With over 3,000 clients globally, NAMSA aims to ensure a seamless transition for Labcorp's clients while maintaining exceptional service standards. The integration of Labcorp's Early Development capabilities aligns perfectly with NAMSA’s mission to streamline solutions and provide robust support for medical device development. This strategic enhancement also positions NAMSA to better meet the growing demands of the MedTech industry, where innovation and regulatory compliance are paramount.
NAMSA's operational footprint expands with this acquisition, as it plans to conduct future projects for Labcorp's Early Development clients across its facilities in Ohio, Minnesota, Georgia, and California. This move marks NAMSA's tenth acquisition since joining ARCHIMED, a global private equity firm focused on healthcare, in 2020. Brian Caveney, EVP and President of Labcorp's Early Development Research Laboratories, expresses confidence in NAMSA’s ability to uphold high standards of service and expertise, allowing Labcorp to focus on its core preclinical drug development and chemical testing activities.
In addition to enhancing its service portfolio, NAMSA’s acquisition is a vital component of its strategy to lead in the medical device testing landscape. Established in 1967, the company is dedicated to accelerating medical device product development through its extensive knowledge and capabilities in testing and regulatory compliance. This acquisition not only underscores NAMSA's growth ambitions but also reinforces its role as a crucial partner for medical device innovation and healthcare advancement.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

